Arcturus Therapeutics (ARCT) Tops Q2 EPS by 21c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.84), $0.21 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.96 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Quantum BioPharma gets FDA clearance for MS drug phase 2 trial
• Vulcan Infrastructure adds three directors after $39.4M investment